831 related articles for article (PubMed ID: 26961900)
21. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
22. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
23. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
24. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
Sanchez C; Chan R; Bajgain P; Rambally S; Palapattu G; Mims M; Rooney CM; Leen AM; Brenner MK; Vera JF
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):123-31, S1. PubMed ID: 23295316
[TBL] [Abstract][Full Text] [Related]
25. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
26. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
27. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
28. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
29. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
30. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Li H; Zhao Y
Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
[TBL] [Abstract][Full Text] [Related]
31. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
33. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
34. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.
Tang XJ; Sun XY; Huang KM; Zhang L; Yang ZS; Zou DD; Wang B; Warnock GL; Dai LJ; Luo J
Oncotarget; 2015 Dec; 6(42):44179-90. PubMed ID: 26496034
[TBL] [Abstract][Full Text] [Related]
36. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
37. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
38. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
39. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
40. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
